Isabelle Toubia1,2, Christophe Nguyen3, Stéphane Diring1, Marine Pays3, Elodie Mattana3, Philippe Arnoux2, Céline Frochot2, Magali Gary-Bobo3, Marwan Kobeissi4, Fabrice Odobel1. 1. CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, CNRS, UMR CNRS 6230, Université de Nantes, 2, rue de la Houssinière-BP 92208, CEDEX 3, 44322 Nantes, France. 2. LRGP, Laboratoire Réactions et Génie des Procédés, UMR 7274 CNRS-Université de Lorraine, 1 rue Grandville, 54000 Nancy, France. 3. IBMM, Université de Montpellier, CNRS, ENSCM, 34093 Montpellier, France. 4. Laboratoire Rammal Rammal, Equipe de Synthèse Organique Appliquée SOA, Faculté des Sciences 5, Université Libanaise, Nabatieh, Lebanon.
Abstract
The combination of photodynamic therapy and chemotherapy is a promising strategy to enhance cancer therapeutic efficacy and reduce drug resistance. In this study two zinc(II) phthalocyanine-tin(IV) conjugates linked by a triethylene glycol chain were synthesized and characterized. In these complexes, the zinc(II) phthalocyanine was used as a potential photosensitizer for PDT and the tin complex was selected as cytostatic moiety. The two dyads composed of zinc(II) phthalocyanine and tin complexes exhibited high cytotoxicity, in absence of light stimulation, against MCF-7 human breast cancer cells with low LC50 values in the range of 0.016-0.453 µM. In addition, these complexes showed superior cytotoxicity than their mixture of equimolar component, accompanied with a higher activity towards cancer cells compared to human healthy fibroblasts. However, under irradiation of the zinc phthalocyanine unit (at 650 nm) no photodynamic activity could be detected, due to the most likely quenching of zinc(II) phthalocyanine singlet excited state by the nearby tin complex according to a photoinduced electron transfer process. This study demonstrates the potential of heterometallic anticancer chemotherapeutics composed of a zinc phthalocyanine and tin complex, and it highlights that the development of such conjugates requires that the sensitizer preserves its photophysical properties and in particular its singlet oxygen sensitization ability in the conjugate in order to combine the PDT activity with the cytotoxicity of the anticancer drug.
The combination of photodynamic therapy and chemotherapy is a promising strategy to enhance pan class="Disease">cancer theraclass="Chemical">peutic efficacy and reduce drug resistance. In this study two class="Chemical">pan class="Chemical">zinc(II) phthalocyanine-tin(IV) conjugates linked by a triethylene glycol chain were synthesized and characterized. In these complexes, the zinc(II) phthalocyanine was used as a potential photosensitizer for PDT and the tin complex was selected as cytostatic moiety. The two dyads composed of zinc(II) phthalocyanine and tin complexes exhibited high cytotoxicity, in absence of light stimulation, against MCF-7humanbreast cancer cells with low LC50 values in the range of 0.016-0.453 µM. In addition, these complexes showed superior cytotoxicity than their mixture of equimolar component, accompanied with a higher activity towards cancer cells compared to human healthy fibroblasts. However, under irradiation of the zinc phthalocyanine unit (at 650 nm) no photodynamic activity could be detected, due to the most likely quenching of zinc(II) phthalocyanine singlet excited state by the nearby tin complex according to a photoinduced electron transfer process. This study demonstrates the potential of heterometallic anticancer chemotherapeutics composed of a zinc phthalocyanine and tin complex, and it highlights that the development of such conjugates requires that the sensitizer preserves its photophysical properties and in particular its singlet oxygen sensitization ability in the conjugate in order to combine the PDT activity with the cytotoxicity of the anticancer drug.
Entities:
Keywords:
chemotherapy; photodynamic therapy; tin complex; zinc (II) phthalocyanine
Authors: V Kirveliene; G Grazeliene; D Dabkeviciene; I Micke; D Kirvelis; B Juodka; J Didziapetriene Journal: Cancer Chemother Pharmacol Date: 2005-11-05 Impact factor: 3.333
Authors: Magda van Leeuwen; Andrew Beeby; Isabelle Fernandes; Stephen H Ashworth Journal: Photochem Photobiol Sci Date: 2013-11-06 Impact factor: 3.982
Authors: Rubén Ruiz-González; Paula Milán; Roger Bresolí-Obach; Juan Carlos Stockert; Angeles Villanueva; Magdalena Cañete; Santi Nonell Journal: Cancers (Basel) Date: 2017-02-17 Impact factor: 6.639
Authors: Mikhail Grin; Nikita Suvorov; Petr Ostroverkhov; Viktor Pogorilyy; Nikita Kirin; Alexander Popov; Anna Sazonova; Elena Filonenko Journal: Biophys Rev Date: 2022-06-09